• Teaser
  • Kapseln
  • Teaser
  • Teaser

GMP Chitosan, medical device chitosan, pure chitin, pharma chitosan, chitosan derivatives, GMP, Quality, producer | Heppe Medical Chitosan

SARS-CoV-2 research with chitosan - publications to date

The corona virus disease COVID-19 has changed the world. To combat the pandemic, researchers and companies around the world are working to develop vaccines and medicines. Chitosan also has potential in the area of vaccine development and functionalization of protective equipment such as respirators. We have prepared summaries of recent publications on chitosan as an aid in the fight against corona.

Chitosan for vaccine development against SARS-CoV-2

The global spread of SARS-CoV-2 can only be contained through vaccine development. Vector vaccines (DNA and viral) can be produced rapidly and inexpensively with current synthesis technologies. Challenges with DNA vaccines include degradation by DNases, inefficient uptake by antigen-presenting cells, and low immunogenicity. The Quil-A-loaded chitosan particulate adjuvant system (QAC) enables transport of plasmid DNA directly to target cells and delayed release over time. Here, we present two recent studies about chitosan-based delivery systems for vaccines.

Respirators with chitosan nanoparticles as protection against SARS-CoV-2 infection

In the current corona pandemic, the protection of medical personnel who have contact with Covid-19 infected patients is important, also to ensure stability of the health care services. The personal protective equipment of hospital staff includes particle filtering respiratory masks. From early 2021, a clinical study will be conducted to investigate the protective effect of a new type of respirator with a filter element containing chitosan nanoparticles in Brazil. More about this study and other current clinical studies with chitosan in this article.

Chitosan against Corona? Substituted chitosan as effective inhibitor of SARS-CoV-2 and MERS-CoV

The new corona virus SARS-CoV-2 has spread globally, originating from China since the beginning of the year. The pathogen causes the lung disease Covid-19 and has been classified as a pandemic since March 11, 2020. Researchers around the world are working on the development of effective vaccinations and drugs. A current study examined the antiviral effectiveness of HTCC (N- (2-hydroxypropyl) -3-trimethylammonium chitosan chloride) in vitro and ex vivo against the new coronavirus SARS-CoV-2 and MERS-CoV.

Congress and fairs

Meet us in person 2023:

  • EASO Winterschool 2023, Wittenberg, Germany, 15.02.-18.02.2023
  • EUCHIS 2023, Siglufjörður, Iceland, 11.-14.09.2023
  • EPNOE 2023, Graz, Austria, 18.09.-22.09.2023
  • Asia Pacific Chitin and Chitosan Symposium 2023, Juju, South-Korea, 31.10.-03.11.2023
  • Bioeconomy Innovation Day, Brussels, Belgium, 16.11.2023

To arrange an appointment please contact Katja Richter via sales(at)medical-chitosan.com

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2024 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.